Viking Therapeutics Stock Plunges on Clinical Trial Concerns
Published on 10/15/2025 at 10:27 | Redaktion boerse-global.de
Viking Therapeutics is experiencing the downside of its ambitious growth strategy. Recent clinical developments have tempered investor enthusiasm for the biotech firm, sending shares downward despite previous monthly gains. The primary concern stems from high discontinuation rates observed in trials for the company’s oral weight loss medication.
The company’s latest quarterly report reveals significant financial pressure. During the second quarter of 2025, research and development expenditures surged to $60.2 million—more than double the $23.8 million recorded during the same period last year.
This explosive cost growth has dramatically impacted the bottom line. Viking’s net loss widened substantially to $65.6 million, compared to $22.3 million in the prior year period. While the company maintains solid cash reserves,... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
